Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 3/20 | 0.43 |
| ▸ | XRCC6 | P12956 | 1/20 | 0.43 |
| ▸ | XRCC5 | P13010 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611151 | 1.00 | FGFR1 (0.53) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL29468205 | 0.84 | FGFR1 (0.49) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL24329827 | 0.84 | FGFR1 (0.49) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL26912263 | 0.83 | LRRK2 (0.57) | FGFR1FLT1ITKLRRK2MAPK1 | |
| SCHEMBL30611169 | 0.82 | ELANE (0.46) | FGFR1FLT1ITKELANEFAAH | |
| SCHEMBL24331552 | 0.82 | ELANE (0.46) | FGFR1FLT1ITKELANEFAAH | |
| SCHEMBL24331250 | 0.81 | LRRK2 (0.57) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL29468163 | 0.81 | LRRK2 (0.57) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL24330017 | 0.81 | FGFR1 (0.46) | FGFR1FLT1ITKELANELRRK2 | |
| SCHEMBL24330431 | 0.81 | FGFR1 (0.52) | FGFR1FLT1ITKELANELRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | claimed |
| CN-116568684-A | Novel compounds | AC免疫有限公司 | 2023-08-08 | — | — | CN | claimed |
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| CN-116568684-A | Novel compounds | AC免疫有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | FGFR1 4148/4885FLT1 4639/4885ITK 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.